Cancer Clinical Trials Optimization and Pharmacogenomics by I. C. Baianu
Preprint         
Cancer Clinical Trials Optimization and Pharmacogenomics 
I. C. Baianu 
AFC-NMR & NIR Microspectroscopy Facility, 
College of ACES, FSHN & NPRE Departments, 
University of Illinois at Urbana, 
Urbana, IL. 61801, USA 
Email address: ibaianu @illinois.edu 
                                                      Date:  02/05/2012                                  
To optimize the survival of patients in cancer clinical trials requires that rational, pharmacogenomic 
strategies in cancer clinical trials be adopted which include specific molecular targeting cancer cells that 
are resistant to existing cancer therapies.  Such novel strategies must be based on adequate cancer 
genomics data [1] and on a detailed understanding/modeling of cancer cell genomes, the modifications 
of cancer signaling pathways and the epigenetic mechanisms involved in cancer. It can be said in  
general that “all cancers arise as a result of changes that have occurred in the DNA sequence 
of the genomes of cancer cells” [1].  Cancer research and clinical trials are now moving into a 
completely new phase in which it has become feasible to obtain the complete DNA sequences for large 
numbers of cancer genomes that would provide essential information on how individual cancers have 
developed in specific patients. Novel translational oncogenomics research [2] is thus rapidly expanding 
through the application of highly sensitive and specific advanced technology, novel research findings, 
computational tools and complex models utilized to solve to both pharmaceutical and clinical problems. 
Multiple sample analyses from several recent clinical studies have shown that gene expression data for 
cancer cells can be employed to distinguish between tumor types as well as to predict outcomes. 
Potentially important applications of such results are individualized human cancer therapies [2-4] or, in 
general, ‘personalized medicine’ that will have to be validated through optimally designed clinical trials 
in cancer [4].  Such treatments based on personalized medicines form the subject of the new field of 
Pharmacogenomics. 
Carcinogenesis is a very complex process that involves dynamically inter-connected biomolecules in the 
intercellular, membrane, cytosolic, nuclear and nucleolar compartments that form numerous inter-
related pathways referred to as networks [2-6]. One such family of signaling pathways contains the cell 
cyclins.  Cyclins are often over-expressed in cancerous cells [6]. This provides a basis for the 
development of novel rational chemotherapies and chemoprevention of cancers.  Cyclins are proteins 
that link several critical pro-apoptotic and other cell cycling/division components, including the tumor 
suppressor gene TP53 and its product, the Thomsen-Friedenreich antigen (T- F antigen), Rb, mdm2, c-
Myc, p21, p27, Bax, Bad and Bcl-2, which all play major roles in carcinogenesis of many cancers.  Cyclin-
dependent kinases (CDK), their respective cyclins, and inhibitors of CDKs (CKIs) were identified as 
instrumental components of the cell cycle-regulating machinery.  CDKs are enzymes that phosphorylate 
several cellular proteins thus ‘fueling’ the sequential transitions through the cell division cycle. The 
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analysis of cancer models including CDKs and signaling pathways suggests the possibility of optimizing 
novel clinical trials through the development of  rational therapies of cancer and the possibility of re-
establishing cell cycling inhibition in metastatic cancer cells without subsequent transformations that 
lead to drug resistance [4] 
On the one hand, quite remarkable progress has been made with cancer treatments through a handful 
of such clinical trials targeting cancer signaling pathways over the last decade [2-4, 7-22]. This is the case 
especially with lung cancer treatments where new classes of anti-cancer medicines were thoroughly 
tested [23], and the development of a few new anti-cancer drugs which involved rational pharmacology 
[24,25], as for example in the case of Imatinib. Such novel anti-cancer drugs were found to prolong 
cancer patient lives significantly for large numbers of lung cancer patients. However, many other drugs 
tested in numerous cancer clinical trials were shown not to have a significant impact on the growth of 
malignant tumors, and thus, did not have any positive outcomes for cancer treatments.  It is therefore 
surprising that such unsuccessful or unremarkable compounds are currently still being tested in cancer 
clinical trials in several large countries. Several such controversial, cancer clinical trials in a few foreign 
countries may be only financially-driven, rather than being rational as advocated in this article.  The 
critical need for optimizing clinical trials in cancer could only be satisfied by multi-disciplinary teams that 
can obtain both the necessary cancer genomics data and corroborate such individualized cancer genome 
data with carefully analyzed progress of the individualized treatments of the cancer patients involved in 
well-designed clinical trials.  
On the other hand, in spite of the remarkable progress made in cancer chemotherapy through clinical 
trials with novel anti-cancer drugs, the expected `magic bullet’ for a complete treatment of cancers has 
not yet been found, and most of the clinical trials were not optimized for the maximum possible length 
of survival of the largest number of cancer patients involved in such advanced stage cancer trials. The 
latter fact raises the important issue of designing rational strategies for clinical trials in cancer that 
would optimize the survival rates of the maximum possible number of patients undergoing new clinical 
trials in cancer. The number of new anti-cancer drugs proposed for testing in cancer clinical trials is on a 
fast rise, and there is, therefore, an added urgency for maximizing cancer patients’ survival in such 
clinical trials through a rational selection of new drugs and optimal treatment strategies based on a 
knowledge of the specific cancer genomes involved. Only five years ago, this approach would not have 
been technically feasible on the time scale of typical clinical trials, and it would also have been 
prohibitively expensive. Optimized cancer patient survival in clinical trials is now possible through multi-
disciplinary approaches and high-throughput, low-cost analysis of cancer genomics [26-28, 36], 
interactomics/proteomics [29-36] and epigenetics [36, 37].  
The critical part of all such optimized cancer clinical (OCC) trials involves learning how to deal with the 
drug-resistant malignant tumor subpopulations of cancer patients that were previously treated only 
with very limited success.  The determination of the complete, individual cancer genomes present in 
such therapy-resistant cancer cell subpopulations [1] is therefore critical for the success of optimized 
clinical trials that maximize the survival rates of the cancer patients involved in the OCC trials.  
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